AI News Sentiment & Analysis
Pliant Therapeutics, Inc. (PLRX) — AI News Sentiment & Analysis
3 recent AI analyses of Pliant Therapeutics, Inc. (PLRX) stock news and press releases, with sentiment and confidence scoring updated continuously.
Pliant Therapeutics Announces First Patient Dosed in FORTIFY, the Phase 1b Indication Expansion Trial Evaluating PLN-101095 in Patients with ICI-Refractory Solid Tumors
BullishClinical ResultsDosing the first patient in the Phase 1b FORTIFY clinical trial for PLN-101095 marks verifiable progress in Pliant Therapeutics' lead oncology program. (Timing: Interim data for this trial is expected in 2027, providing a medium-term milestone.)Apr 30, 2026Pliant Therapeutics Announces Presentation of Updated Data from the Phase 1 Trial of PLN-101095 in Patients with ICI-Refractory Solid Tumors at the 2026 AACR Annual Meeting
BullishUpdated positive Phase 1 clinical trial data for PLN-101095 presented at AACR 2026 Annual Meeting, showing deep responses and prolonged treatment times. (Timing: Immediate market re-evaluation at the next market open, with further data expected in 2027 from the Phase 1b expansion trial.)Apr 18, 2026Pliant Therapeutics Announces Upcoming Presentation of Phase 1 Clinical Trial of PLN-101095 in Patients with Solid Tumors at the 2026 AACR Annual Meeting
BullishPresentation of Phase 1 clinical trial data for PLN-101095 in solid tumors at the AACR Annual Meeting. (Timing: April 18, 2026)Mar 18, 2026
Want the full picture?
These are AI-read press-release catalysts. Sign up to see complete investment theses, valuation rationales, entry/exit strategies, and get real-time alerts.
Sign Up for FreeFrequently Asked Questions
Is Pliant Therapeutics, Inc. (PLRX) bullish or bearish right now?
AI Sentiment on PLRX: 3 Bullish.
What was the latest AI analysis for Pliant Therapeutics, Inc. (PLRX)?
The latest analysis was published on 4/30/2026 with the headline: "Pliant Therapeutics Announces First Patient Dosed in FORTIFY, the Phase 1b Indication Expansion Trial Evaluating PLN-101095 in Patients with ICI-Refractory Solid Tumors".
How does Bekodia analyze Pliant Therapeutics, Inc. (PLRX) stock?
Bekodia uses advanced AI models to process Pliant Therapeutics, Inc. (PLRX) press releases and news in real-time, extracting sentiment, confidence scores, and key investment catalysts while filtering out market noise.